![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Summary
Novelty: The antiviral therapy (particularly the therapy of human immunodeficiency virus (HIV) infection), using a gp120 stripping agent is described, denoted ST4. Such agents remove at least a portion of gp120 from the surface of HIV or virus infected cells, decreasing the infectivity of the virus.
Biology: Data relating to the interaction of ST4 and HIV and HIV-infected cells are provided. A reduction in the surface density of glycoprotein spikes on the surface of mature HIV virus is shown. Bolus injection of ST4 in mice shows no histopathological changes, and shows significant IgM response. Human T-cell glycoprotein CD4 (previously called T4) is the receptor to which the virus binds. A monoclonal antibody against CD4 blocks HIV infection. ST4 is soluble recombinant CD4 which binds gp120 inhibiting infection.
Preferred Compound: Stripping agent which is a soluble CD4 or a gp120 binding derivative is specifically claimed.